A Retrospective, Longitudinal, Observational, Multicentric Study to Assess Predictors of Survival of Secukinumab Treatment in a Multicenter Cohort of Patients with Spondylarthritis
Latest Information Update: 01 Jul 2020
Price :
$35 *
At a glance
- Drugs Secukinumab (Primary)
- Indications Axial spondyloarthritis; Psoriatic arthritis; Spondylarthritis
- Focus Adverse reactions; Therapeutic Use
- 06 Jun 2020 Results (n=561) evaluating predictors of drug maintenance of Secukinumab Spondylarthritis, presented at the 21st Annual Congress of the European League Against Rheumatism
- 10 Feb 2020 New trial record